Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

Browse, watch, read, and learn more.

Helpful information for patients with invasive breast cancer.

FAQs

Videos

86%
of Breast Recurrence Score test patients have $0 financial responsibility*

This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid, and commercial insurance. Patient cost-sharing amounts, including deductibles and copays, will vary by plan and coverage type. Only your insurer can confirm if and how Breast Recurrence Score test will be covered.

91%
of Breast Recurrence Score test patients have a financial responsibility of <$100*

This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid, and commercial insurance. Patients with high-deductible plans may receive a bill for most or all the cost of the Breast Recurrence Score test if they have not satisfied their deductible.

* Testing performed at an Exact Sciences clinical lab in Redwood City, CA (Genomic Health, Inc.).

† The numbers cited are based on historical patient billing data from 1/2/2021 to 12/31/2021. Rates of coverage vary by state and region. Exceptions for coverage may apply. Exact Sciences strongly encourages you to contact your insurer with questions about Oncotype DX Breast Recurrence Score test coverage.